# Vorasidenib Maintenance for IDH Mutant Astrocytoma

> **NCT06809322** · PHASE3 · RECRUITING · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 468 (estimated)

## Conditions studied

- IDH-mutant Grade 2 or 3 Astrocytoma

## Interventions

- **DRUG:** Vorasidenib
- **DRUG:** Vorasidenib Placebo

## Key facts

- **NCT ID:** NCT06809322
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2035-04-13
- **Final completion:** 2037-05-31
- **Target enrollment:** 468 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06809322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06809322, "Vorasidenib Maintenance for IDH Mutant Astrocytoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06809322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*